Adaptive Biotechnologies Corporation Overview
ADPT market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
ADPT price chart · 1M
- O
- 26.99
- H
- 28.17
- L
- 26.58
- C
- 26.58
- Vol
- 143,444.00
Daily history from Jun 27, 2019
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $26.99
- Previous Close
- $26.80
- Day High
- $28.17
- Day Low
- $26.58
- 52 Week High
- $30.74
- 52 Week Low
- $12.01
- 7 Day Return
- -0.19%
- 30 Day Return
- +1.14%
- 90 Day Return
- +4.42%
- 1 Year Return
- +71.04%
- Daily Notional Volume
- $3.8M Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.39 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.17 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -20.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $12.00 – $30.74 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $4.3B · P/B 11.33 · P/S 13.88.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
10 captured
Adaptogenics Health Corp. Engages InvestorBrandNetwork for Corporate Communications StrategyFiscal.ai ·
Telo Genomics Expands Comparative Evaluation of TELO-MRD Against Adaptive Biotechnologies' clonoSEQFiscal.ai ·
Decision & ScoreThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
Trend & Pattern EvidenceThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
Sector Peer RankingThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
AI-selected reference, checked against source evidence · Evidence observed
Frequently Asked QuestionsSource-linked answers to common questions about this asset. Check the evidence observation date and whether the reference was reviewed by a person.
- What business does Adaptive Biotechnologies Corp operate?
- Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.
- Which industry is Adaptive Biotechnologies Corp classified in?
- The SEC company record classifies Adaptive Biotechnologies Corp under Biological Products, (No Diagnostic Substances). This filing classification provides industry context alongside the provider's business description.
What to WatchAI-assisted topics for further research about this asset. These are educational prompts, not trading signals or recommendations.
- Business activities described in the company reference
- Original company disclosures and industry classification